Apprentice day: APPRENTICESHIP AT EUROIMMUN is capital(ised)!

EUROIMMUN has been successfully training young talents since 1995. Whether in the laboratory, the warehouse, the restaurant, IT or technical departments, or in administration  ̶  at EUROIMMUN, everyone can find an assignment which they enjoy! The new apprentices start their vocational training in August and September. For a smooth start, they are invited together with […]

EUROIMMUN-Entwickler belegten beim HanseHack Lübeck den zweiten Platz

HanseHack Lübeck: EUROIMMUN developers rank 2nd

The event HanseHack Lübeck took place on the 6th and 7th September 2018 and was all about “connecting Lübeck”. The basis for “Smart City” concepts to be developed was a city-wide LoRaWAN (Long Range Wide Area Network) net provided by the company TraveKom. This net allows reception of sensor data over large distances and collection

Tag der offenen Tür bei EUROIMMUN in Dassow

Behind the scenes: Open day at EUROIMMUN

One in three adults in Germany suffers from allergies, new infectious diseases are spreading, and in some people, the immune system is fighting against their own body. For over 30 years, EUROIMMUN has been developing test systems for fast and reliable detection of these conditions. But how exactly does this work and what role do


2nd GPCR Symposium 2018 from 28th – 30th September 2018 in Luebeck (Germany)

G-protein-coupled receptors (GPCR) are transmembrane proteins involved in various physiological and pathophysiological processes and signalling pathways. Due to their key role, they have been in the focus of science and industry for the past decades to search for new diagnostic markers and pharmaceuticals for the treatment of various diseases. Already around 30% of the therapeutic


Recording of the webinar on measles and mumps

Measles and mumps, two forgotten diseases, reveal an unfortunate comeback. In a free webinar on February 15th, Oliver Sendscheid, PhD, Scientific Director at EUROIMMUN US, and Rolando Pajon, PhD, Lead Scientist for Vaccine and Novel Immunotherapeutic Laboratory Solutions at COVANCE CLS addressed the current epidemiologic status of measles and mumps, challenges and solutions in serological testing,

Scroll to Top